Salvage chemotherapy for metastatic germ cell tumours: The known unknowns

Por Hansen, Aaron R., Bedard, Philippe L.
Publicado em 2012

Clinical application of high-throughput genomic technologies for treatment selection in breast cancer

Por Hansen, Aaron R, Bedard, Philippe L
Publicado em 2013

Early phase clinical trials to identify optimal dosing and safety

Por Cook, Natalie, Hansen, Aaron R., Siu, Lillian L., Abdul Razak, Albiruni R.
Publicado no Mol Oncol (2014)

Tumour heterogeneity in the clinic

Por Bedard, Philippe L., Hansen, Aaron R., Ratain, Mark J., Siu, Lillian L.
Publicado no Nature (2013)

Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials

Por Hansen, Aaron R., Cook, Natalie, Ricci, M. Stacey, Razak, Albiruni, Le Tourneau, Christophe, McKeever, Kathleen, Roskos, Lorin, Dixit, Rakesh, Siu, Lillian L., Hinrichs, Mary Jane
Publicado no Oncologist (2015)

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

Por Stockley, Tracy L., Oza, Amit M., Berman, Hal K., Leighl, Natasha B., Knox, Jennifer J., Shepherd, Frances A., Chen, Eric X., Krzyzanowska, Monika K., Dhani, Neesha, Joshua, Anthony M., Tsao, Ming-Sound, Serra, Stefano, Clarke, Blaise, Roehrl, Michael H., Zhang, Tong, Sukhai, Mahadeo A., Califaretti, Nadia, Trinkaus, Mateya, Shaw, Patricia, van der Kwast, Theodorus, Wang, Lisa, Virtanen, Carl, Kim, Raymond H., Razak, Albiruni R. A., Hansen, Aaron R., Yu, Celeste, Pugh, Trevor J., Kamel-Reid, Suzanne, Siu, Lillian L., Bedard, Philippe L.
Publicado no Genome Med (2016)